-
ALSO READ
Biocon set for bigger insulin play, aims to reach one in five diabetics
Sun Pharma's diabetes NCE show promise; to go into phase 1 trials in Q3
Biocon gets a shot in the arm with FDA approval for insulin glargine
AstraZeneca Pharma hits fresh record high of Rs 4,489; stock surges 15%
Biocon diversifies business model, enters digital therapeutic segment
-
Aiming to touch the lives of 10 million diabetics in three years, biopharmaceutical major AstraZeneca India has joined hands with the Research Society for Study of Diabetes in India (RSSDI) to drive awareness about the disease digitally in order to prevent complications arising from the uncontrolled incidence of diabetes.
Reports show that India will have around 115 million diabetics by 2030. Forty-four per cent of patients hospitalised for heart failure have type-2 diabetes showcasing the steep correlation between diabetes and the latter. Therefore, it is critical that diabetes be controlled to decrease the incidence of heart failure in India, said the Bengaluru-based company.
“We will be leveraging digital channels such as social media to empower diabetes patients so they are able to act early on to manage and prevent complications related to the disease,” said Anil Kukreja, Vice President – Medical Affairs & Regulatory, AstraZeneca India.
While RSSDI is the largest organisation of diabetes health care professionals and researchers in Asia, AstraZeneca India has the marketing licence to sell blockbuster anti-diabetic drug Dapagliflozin for the treatment of heart failure. Sold under the brand name Forxiga, it had a $1.54 billion market in 2019. The British pharmaceutical parent of AstraZeneca India is currently fighting a court case to prevent about 12 Indian pharma companies from manufacturing and selling low cost versions of this medicine.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
